Xevinapant Fails Phase 3 in Head and Neck Cancer

Patients with unresected locally advanced head and neck cancer had worse outcomes when they received xevinapant along with standard chemoradiotherapy.
Medscape Medical News

source https://www.medscape.com/viewarticle/xevinapant-fails-phase-3-head-and-neck-cancer-2025a1000qqb?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension